These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9510499)

  • 1. A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease.
    Miller TP; Chase EM; Dorr R; Dalton WS; Lam KS; Salmon SE
    Anticancer Drugs; 1998 Feb; 9(2):135-40. PubMed ID: 9510499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma.
    Sarris AH; Younes A; McLaughlin P; Moore D; Hagemeister F; Swan F; Rodriguez MA; Romaguera J; North L; Mansfield P; Callendar D; Mesina O; Cabanillas F
    J Clin Oncol; 1996 Jan; 14(1):233-9. PubMed ID: 8558203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
    Borghaei H; Millenson M; Schilder R; Alden M; Rogatko A; Wang H; Padavic-Shaller K; Smith MR
    Cancer; 2004 Nov; 101(9):2034-41. PubMed ID: 15455357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.
    Murren JR; Peccerillo K; DiStasio SA; Li X; Leffert JJ; Pizzorno G; Burtness BA; McKeon A; Cheng Y
    Cancer Chemother Pharmacol; 2000; 46(1):43-50. PubMed ID: 10912577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
    Kahl BS; Bailey HH; Smith EP; Turman N; Smith J; Werndli J; Williams EC; Longo WL; Kim KM; McGovern J; Jumonville A
    Cancer Invest; 2005; 23(1):13-8. PubMed ID: 15779863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
    Rowinsky EK; Smith L; Wang YM; Chaturvedi P; Villalona M; Campbell E; Aylesworth C; Eckhardt SG; Hammond L; Kraynak M; Drengler R; Stephenson J; Harding MW; Von Hoff DD
    J Clin Oncol; 1998 Sep; 16(9):2964-76. PubMed ID: 9738565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma.
    Abbasi MR; Sparano JA; Sarta C; Wiernik PH
    Med Oncol; 2003; 20(1):53-8. PubMed ID: 12665685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
    Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
    Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma.
    Younes A; Rodriguez MA; McLaughlin P; North L; Sarris AH; Pate O; Hagemeister FB; Romaguera J; Preti A; Bachier C; Cabanillas F
    Leuk Lymphoma; 1997 Jun; 26(1-2):77-82. PubMed ID: 9250790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
    Pro B; Hagemeister FB; McLaughlin P; Romaguera J; Rodriguez MA; Cabanillas F; Tiongson LP; Younes A
    Leuk Lymphoma; 2006 Sep; 47(9):1818-21. PubMed ID: 17064994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Younes A; Romaguera J; Mesina O; Hagemeister F; Sarris AH; Rodriguez MA; McLaughlin P; Preti HA; Bachier C; Cabanillas F
    Br J Haematol; 1998 Dec; 103(3):678-83. PubMed ID: 9858216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study for the evaluation of quinine as a modulator of multidrug resistance in non-Hodgkin's lymphoma.
    Soubeyran P; Masmoudi A; Blanc-Bisson C; Quénel N; Hoerni B; Bellott R; Robert J; Soubeyran I; Donamaria C; Molimard M
    Eur J Cancer; 2007 Jan; 43(1):53-4. PubMed ID: 16824747
    [No Abstract]   [Full Text] [Related]  

  • 13. Paclitaxel-based treatment of lymphoma.
    Younes A
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):123-8. PubMed ID: 10190794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial.
    Stemmer SM; Cagnoni PJ; Shpall EJ; Bearman SI; Matthes S; Dufton C; Day T; Taffs S; Hami L; Martinez C; Purdy MH; Arron J; Jones RB
    J Clin Oncol; 1996 May; 14(5):1463-72. PubMed ID: 8622060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.
    Press OW; LeBlanc M; O'Rourke TJ; Gagnet S; Chapman RA; Balcerzak SP; Fisher RI
    J Clin Oncol; 1998 Feb; 16(2):574-8. PubMed ID: 9469343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas.
    Wilson WH; Chabner BA; Bryant G; Bates S; Fojo A; Regis J; Jaffe ES; Steinberg SM; Goldspiel BR; Cheson BD
    J Clin Oncol; 1995 Feb; 13(2):381-6. PubMed ID: 7531220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial.
    Younes A; Ayoub JP; Sarris A; Hagemeister F; North L; Pate O; McLaughlin P; Rodriguez MA; Romaguera J; Kurzrock R; Preti A; Bachier C; Smith T; Cabanillas F
    Br J Haematol; 1997 Feb; 96(2):328-32. PubMed ID: 9029021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
    Klaassen U; Wilke H; Seeber S
    J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
    Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.